AUPH News and Press, Aurinia Pharmaceuticals Inc From 04/28/23

Leading independent proxy advisor also recommends shareholders vote for say-on-pay, equity incentive plan amendment, and appointment of auditors Company reminds shareholders to vote today to protect the value of their investment and ensure Aurinia’s continued momentum Share...

Braxton, a seven-time Grammy Award-winning singer, songwriter, actress, producer, and entrepreneur, will share her personal lupus journey to empower people with lupus and lupus nephritis to prioritize their kidney health as part of Aurinia’s Get Uncomfortable campaign The Get Uncom...

2023-04-24 12:18:08 ET MKT Capital, which owns 4.2% of the outstanding shares of Aurinia Pharmaceuticals ( NASDAQ: AUPH ), is calling on the company to put itself up for sale. In a Monday letter to shareholders, MKT writes that a "reconstituted board" should "commence a stra...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the first quarter of 2023, on Thursday, May 4, 2023, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am...

2023-04-24 05:31:06 ET Summary Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. Biotech deal-making has been increasing, with large acquisitions such as Pfizer's acquisit...

2023-04-11 14:41:12 ET Aurinia Pharmaceuticals (NASDAQ: AUPH) , a small-cap commercial-stage drugmaker, is having another strong session today. Specifically, the biotech's stock was up by 11.9% on moderate volumes as of 1:51 p.m. ET Tuesday afternoon. Following this latest doubl...

New method of use patent (U.S. Patent No. 11,622,991) issued for LUPKYNIS Reflects the unique and proprietary dosing regimen indicated for LUPKINIS in Lupus Nephritis Announcement is a follow-up to previously announced allowance from the USPTO on application (No. 17,713/140); now ...

2023-04-05 07:07:11 ET Aurinia Pharmaceuticals ( NASDAQ: AUPH ) said biopsy data collected from its phase 3 program AURORA showed promising long term results for its oral drug Lupkynis to treat adults with active lupus nephritis (LN). LN is a type of kidney disease cau...

LUPKYNIS ® treated patients showed histologic activity improvement with stable chronicity scores similar to active control arm of mycophenolate mofetil (MMF) and low dose steroids alone Data further reinforces differentiation of LUPKYNIS from first generation calcineurin inhibito...

2023-03-24 04:47:31 ET Summary Aurinia Pharmaceuticals' Lupkynis revenue figures aren't bad this quarter. However, the target population is the problem. I still think only a buyout from big pharma will unlock full potential. I covered Aurinia Pharmaceuticals ( ...